Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer.

dc.contributor.authorGarrido, Maria Antonia
dc.contributor.authorPerea, Francisco
dc.contributor.authorVilchez, Jose Ramon
dc.contributor.authorRodríguez, Teresa
dc.contributor.authorAnderson, Per
dc.contributor.authorGarrido, Federico
dc.contributor.authorRuiz-Cabello, Francisco
dc.contributor.authorAptsiauri, Natalia
dc.date.accessioned2025-01-07T14:23:35Z
dc.date.available2025-01-07T14:23:35Z
dc.date.issued2021-10-09
dc.description.abstractTotal or partial loss of HLA class I antigens reduce the recognition of specific tumor peptides by cytotoxic T lymphocytes favoring cancer immune escape during natural tumor evolution. These alterations can be caused by genomic defects, such as loss of heterozygosity at chromosomes 6 and 15 (LOH-6 and LOH-15), where HLA class I genes are located. There is growing evidence indicating that LOH in HLA contributes to the immune selection of HLA loss variants and influences the resistance to immunotherapy. Nevertheless, the incidence and the mechanism of this chromosomal aberration involving HLA genes has not been systematically assessed in different types of tumors and often remains underestimated. Here, we used SNP arrays to investigate the incidence and patterns of LOH-6 and LOH-15 in a number of human cancer cell lines and tissues of different histological types. We observed that LOH in HLA is a common event in cancer samples with a prevalence of a copy neutral type of LOH (CN-LOH) that affects entire chromosome 6 or 15 and involves chromosomal duplications. LOH-6 was observed more often and was associated with homozygous HLA genotype and partial HLA loss of expression. We also discuss the immunologic and clinical implications of LOH in HLA on tumor clonal expansion and association with the cancer recurrence after treatment.
dc.identifier.doi10.3390/cancers13205046
dc.identifier.issn2072-6694
dc.identifier.pmcPMC8534100
dc.identifier.pmid34680201
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8534100/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6694/13/20/5046/pdf?version=1634026044
dc.identifier.urihttps://hdl.handle.net/10668/26347
dc.issue.number20
dc.journal.titleCancers
dc.journal.titleabbreviationCancers (Basel)
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de las Nieves
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHLA class I
dc.subjectantigen presentation
dc.subjectbeta2-microglobulin
dc.subjectcancer immune escape
dc.subjectcancer immunotherapy
dc.subjectcopy-neutral loss of heterozygosity (CN-LOH)
dc.subjectcytotoxic T-cells
dc.titleCopy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8534100.pdf
Size:
2.62 MB
Format:
Adobe Portable Document Format